Sarepta Therapeutics will continue to ship its gene therapy delandistrogene moxeparvovec (Elevidys) to ambulant patients with Duchenne muscular dystrophy, despite the FDA's request to halt ...
Despite an FDA request to halt shipments, Sarepta Therapeutics (NASDAQ:SRPT) announced late Friday that the company will continue to ship its gene therapy Elevidys, developed with Roche (OTCQX:RHHBY), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results